Polypharmacy was associated with a nearly doubled increase in health care expenditures and a tripled increase in pharmacy expenditures among older patients with cardiovascular diseases (CVD).
Substantial health care expenditures are associated with polypharmacy among older adults with cardiovascular diseases (CVD), according to findings of a cross-sectional study published in The American Journal of Cardiology.
Polypharmacy is defined as taking at least 5 medications at once, and CVD medications are among the most commonly prescribed treatments. Estimates have projected around 40% of older individuals are subjected to polypharmacy, while between 30% and 50% have been prescribed a potentially inappropriate medication.
Excessive polypharmacy at discharge has also been linked with worse outcomes among those hospitalized with acute decompensated heart failure. Adverse drug reactions and a decline in medication adherence is of particular concern among older patients.
Although older adults with CVD are known to have high rates of comorbidity and polypharmacy, a knowledge gap exists when it comes to this population’s economic impact.
Using data from the 2017 Medical Expenditure Panel Survey, researchers sought to estimate the association between health care expenditure and polypharmacy in older adults. All patients included had CVD and were at least 65 years old, while “the number of prescriptions was defined as the total number of distinct medications that the patient was prescribed during the survey year,” authors wrote.
To ascertain nonpharmacy-related expenditures, researchers subtracted pharmacy-related costs from patients’ total health care expenditures. High blood pressure, coronary heart disease, high cholesterol, and other conditions were among the comorbidities included in the analysis.
Authors also used Poisson regression to determine incidence rate ratios (IRRs); a total of 1610 (weighted total = 17,297,514 older adults) were included in analyses.
Researchers found:
Following adjustments for demographic and clinical factors, data showed polypharmacy “was associated with almost twice the total health care expenditure (198%) and 3 times for pharmacy expenditure (287%),” authors wrote.
Data included were nationally representative, although lack of sufficient follow-up for medication changes marks a limitation to the study. Because of its survey structure, under-reporting may have also taken place.
However, the study is the first to evaluate the economic impact of polypharmacy in this population and can serve as a foundation for future investigations to promote efficiency in health care, authors concluded.
Reference
Kwak MJ, Chang M, Chiadika S, et al. Healthcare expenditure associated with polypharmacy in older adults with cardiovascular diseases. Am J Cardiol. Published online February 12, 2022. doi:10.1016/j.amjcard.2022.01.012
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More